Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 11Head & Neck 4CNS 4Breast 4Sarcoma 3Dermatologic 3Genitourinary 2Tumor-Agnostic 1Thoracic 1Classical hematology 1

Conditions

Skin Neoplasms 1Melanoma 1Eyelid Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 24Specimen Handling 21Nivolumab 20Magnetic Resonance Spectroscopy 16Ipilimumab 12Biopsy 9Cyclophosphamide 5CTLA-4 Antigen 5relatlimab 4Opdualag 4HhAntag691 4trametinib 3fludarabine 3dabrafenib 3cemiplimab 3binimetinib 3avelumab 3aldesleukin 3Surgical Procedures, Operative 3Radiosurgery 3Paclitaxel 3Cisplatin 3Carboplatin 3talimogene laherparepvec 2omipalisib 2capivasertib 2atezolizumab 2X-Rays 2Taxes 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Surgical Procedures, Operative × Dermatologic × 30 days × Clear all
NCT04708418 2026-05-14

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
60 enrolled
Dermatologic

Melanoma

NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06295809 2026-05-08

INTerpath-007

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
46 enrolled
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡